Complete financial analysis of Aldeyra Therapeutics, Inc. (ALDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aldeyra Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zephyrus Wing Energies Ltd (ZPRS.TA) Income Statement Analysis – Financial Results
- Dexus Convenience Retail REIT (DXC.AX) Income Statement Analysis – Financial Results
- Currenc Group, Inc. (CURR) Income Statement Analysis – Financial Results
- Igene Biotechnology, Inc. (IGNE) Income Statement Analysis – Financial Results
- Rapidtek Technologies Inc. (6980.TWO) Income Statement Analysis – Financial Results
Aldeyra Therapeutics, Inc. (ALDX)
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71.00K | 37.85K | 35.79K | 18.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -262.78K | -258.71K | -264.18K | -56.22K | -96.31K | -71.00K | -37.85K | -35.79K | -18.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 29.46M | 47.31M | 44.94M | 24.68M | 44.35M | 29.82M | 16.30M | 13.18M | 7.57M | 3.71M | 1.54M | 469.27K | 1.36M |
| General & Administrative | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.33M | 720.79K | -21.48M | 5.41K |
| Operating Expenses | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.70M | 22.49M | 18.70M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Cost & Expenses | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.70M | 22.49M | 18.70M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Interest Income | 7.32M | 2.35M | 185.36K | 292.22K | 1.54M | 952.70K | 261.25K | 102.04K | 11.13K | 3.00 | 31.00 | 101.00 | 5.00K |
| Interest Expense | 2.07M | 1.69M | 1.74M | 1.90M | 603.85K | 146.79K | 113.45K | 105.51K | 112.31K | 244.17K | 159.32K | 342.01K | 279.93K |
| Depreciation & Amortization | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71.00K | 37.85K | 35.79K | 18.78K | 1.07K | 31.00 | 3.74K | 1.59K |
| EBITDA | -35.21M | -60.07M | -55.77M | -36.07M | -61.44M | -38.68M | -22.19M | -18.56M | -11.96M | -4.94M | 13.22M | -22.73M | -2.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.79M | -62.68M | -56.22M | -36.42M | -63.07M | -39.70M | -22.49M | -18.70M | -11.99M | -7.27M | -3.68M | -1.11M | -2.11M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.25M | 655.35K | -1.56M | -3.37M | -5.63M | 805.91K | 147.80K | -3.47K | -101.18K | 2.08M | 16.74M | -21.96M | -269.53K |
| Income Before Tax | -37.54M | -62.02M | -57.78M | -38.03M | -62.14M | -38.89M | -22.34M | -18.70M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -655.35K | 1.48M | -479.27K | -1.31M | 952.70K | 223.40K | 66.25K | -7.65K | 243.11K | 159.29K | -21.14M | 285.34K |
| Net Income | -37.54M | -61.37M | -59.25M | -37.55M | -60.83M | -38.89M | -22.34M | -18.70M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.05 | -1.10 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.36 | 39.90 | -5.72 | -7.26 |
| EPS Diluted | -0.64 | -1.05 | -1.10 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.35 | 2.72 | -5.10 | -0.50 |
| Weighted Avg Shares Out | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.82M | 327.37K | 4.04M | 327.37K |
| Weighted Avg Shares Out (Dil) | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.85M | 4.80M | 4.52M | 4.80M |
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX) for violations of §§10(b)...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX) for violations of §§10(b)...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ALDX
NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX), and certain officers.
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX) of a class action securities lawsuit.
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Sept. 19, 2023 /PRNewswire/ -- Law Offices of Howard G.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX) for violations of §§10(b)...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)
NEW YORK , Sept. 19, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc..
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX) for violations of §§10(b)...
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Aldeyra Investors of a Lead Plaintiff Deadline of September 29, 2023
NEW YORK , Sept. 18, 2023 /PRNewswire/ -- Attention Aldeyra Therapeutics, Inc. ("Aldeyra") (NASDAQ: ALDX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 17, 2022...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of...
Source: https://incomestatements.info
Category: Stock Reports